Lown-Ganong-Levine syndrome

Lown-Ganong-Levine Syndrome (LGL) is a rare cardiac arrhythmia disorder characterized by a short PR interval on an electrocardiogram (ECG) without the presence of a Wolff-Parkinson-White (WPW) pattern. It is named after Bernard Lown, Samuel A. Levine, and William Ganong, who first described the syndrome in 1952. LGL syndrome is considered a form of pre-excitation syndrome, where the heart's electrical signals travel faster than normal from the atria to the ventricles.

Symptoms and Diagnosis[edit | edit source]

Patients with Lown-Ganong-Levine syndrome may be asymptomatic or present with symptoms related to supraventricular tachycardia (SVT), such as palpitations, dizziness, fainting, or rarely, cardiac arrest. The diagnosis of LGL syndrome is primarily based on the ECG findings of a short PR interval (<120 ms) and the absence of a delta wave, which distinguishes it from WPW syndrome. Additional diagnostic tests, including electrophysiological study (EPS), may be performed to further evaluate the electrical pathways within the heart.

Pathophysiology[edit | edit source]

The pathophysiology of Lown-Ganong-Levine syndrome involves an accessory electrical pathway between the atria and the ventricles, known as the James fiber. Unlike the accessory pathway in WPW syndrome, which conducts electrical signals around the normal conduction system, the James fiber directly connects the atria and the ventricles, bypassing the atrioventricular node (AV node). This results in the rapid transmission of electrical impulses from the atria to the ventricles, leading to the short PR interval observed in LGL syndrome.

Treatment[edit | edit source]

The management of Lown-Ganong-Levine syndrome focuses on controlling symptoms and preventing complications associated with supraventricular tachycardia. Treatment options may include pharmacological agents such as beta blockers, calcium channel blockers, or antiarrhythmic drugs. In some cases, particularly when medication is ineffective or not tolerated, catheter ablation may be considered to disrupt the abnormal electrical pathway and restore normal heart rhythm.

Prognosis[edit | edit source]

The prognosis for individuals with Lown-Ganong-Levine syndrome is generally good, especially when the condition is effectively managed with medication or catheter ablation. However, patients are at an increased risk for developing supraventricular tachycardias and should be monitored regularly for changes in symptoms or heart rhythm.

Epidemiology[edit | edit source]

Lown-Ganong-Levine syndrome is a rare condition, and its exact prevalence is unknown. It can occur in individuals of any age but is most commonly diagnosed in young adults.

A[edit source]

B[edit source]

Brown atrophy of the heart

C[edit source]

D[edit source]

E[edit source]

H[edit source]

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

I[edit source]

K[edit source]

Keshan disease

L[edit source]

Loeffler endocarditis

M[edit source]

N[edit source]

Nonbacterial thrombotic endocarditis

O[edit source]

P[edit source]

R[edit source]

S[edit source]